Health care stocks were edging up late Friday afternoon, with the NYSE Health Care Index and the Health Care Select Sector SPDR Fund (XLV) each adding 0.1%.
The iShares Biotechnology ETF (IBB) shed 0.9%.
In corporate news, Bicycle Therapeutics (BCYC) shares plunged past 31% after it said topline data from a phase 1/2 trial of zelenectide pevedotin plus Merck's (MRK) pembrolizumab showed a 60% overall response rate in first-line metastatic urothelial cancer, in-line with existing therapies.
Candel Therapeutics (CADL) shares sank 30.6% in recent trading, a day after it priced a public offering of 10 million shares at $6 apiece and pre-funded warrants for about 3.3 million shares at $5.99 per warrant to raise about $80 million in gross proceeds.
Walgreens Boots Alliance's (WBA) potential buyer Sycamore Partners contacted banks including Bank of America (BAC), JPMorgan (JPM) and Wells Fargo (WFC) to finance a deal of over $10 billion, Sky News reported. Walgreens shares popped 6.8%.
Centene (CNC) stock is undervalued, now that the company has laid out building blocks on how to operate if enhanced affordable care act, or ACA, exchange subsidies expire after 2025, UBS said. UBS upgraded Centene to buy from neutral. Centene shares rose nearly 3%.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。